Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

AGIO

Agios Pharmaceuticals Inc

Apr 23 • 04:00PM ET

31.81

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF IWN VBR DFAT IBB VBK SCHA

Index	RUT	P/E	-	EPS (ttm)	-6.33	Insider Own	2.59%	Shs Outstand	55.95M	Perf Week	10.45%
Market Cap	1.79B	Forward P/E	-	EPS next Y	-5.89	Insider Trans	-13.03%	Shs Float	54.74M	Perf Month	6.46%
Income	-352.09M	PEG	-	EPS next Q	-1.65	Inst Own	106.21%	Short Float	12.06%	Perf Quarter	46.52%
Sales	26.82M	P/S	66.64	EPS this Y	-5.48%	Inst Trans	-3.01%	Short Ratio	8.69	Perf Half Y	48.78%
Book/sh	14.50	P/B	2.19	EPS next Y	11.85%	ROA	-32.36%	Short Interest	6.60M	Perf Year	40.26%
Cash/sh	13.83	P/C	2.30	EPS next 5Y	39.00%	ROE	-36.83%	52W Range	19.80 - 35.50	Perf YTD	42.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.98%	ROI	-40.56%	52W High	-10.39%	Beta	0.82
Dividend TTM	-	Quick Ratio	11.99	Sales past 5Y	2.66%	Gross Margin	44.95%	52W Low	60.70%	ATR (14)	1.28
Dividend Ex-Date	-	Current Ratio	12.27	EPS Y/Y TTM	-49.22%	Oper. Margin	-1459.52%	RSI (14)	65.70	Volatility	4.67% 4.06%
Employees	383	Debt/Eq	0.09	Sales Y/Y TTM	88.36%	Profit Margin	-1312.63%	Recom	1.67	Target Price	40.67
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-358.63%	Payout	-	Rel Volume	0.00	Prev Close	31.81
Sales Surprise	-10.38%	EPS Surprise	-3.77%	Sales Q/Q	64.80%	Earnings	May 02 BMO	Avg Volume	759.64K	Price	31.81
SMA20	8.85%	SMA50	7.09%	SMA200	24.76%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$80
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy	$117
Apr-11-18	Reiterated	Credit Suisse	Outperform	$80 → $95

Show Previous Ratings

Apr-18-24 07:00AM	Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
Apr-10-24 07:01PM	Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Apr-09-24 07:00AM	Agios Publishes 2024 Environmental, Social and Governance (ESG) Report (GlobeNewswire) +7.26%
Mar-05-24 07:00AM	Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 (GlobeNewswire)
03:12PM	Loading…
Feb-26-24 03:12PM	Agios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating (Investor's Business Daily)
Feb-23-24 10:45AM	Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark (Investor's Business Daily) +10.78%
Feb-22-24 07:00AM	Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 (GlobeNewswire) +11.12%
Feb-20-24 08:24AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-16-24 09:38AM	Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates (Zacks)
Feb-15-24 10:15PM	Q4 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:59AM	Agios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-24 10:00AM	Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline (Zacks)
07:00AM	Loading…
Feb-02-24 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024 (GlobeNewswire)
Jan-24-24 07:02PM	Agios Pharmaceuticals Inc Director Jacqualyn Fouse Sells 10,722 Shares (GuruFocus.com)
Jan-11-24 07:15PM	Insider Sell: CEO Brian Goff Sells 12,066 Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jan-08-24 07:00AM	Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio (GlobeNewswire) +5.66%
Jan-04-24 11:19AM	Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study (Zacks)
07:47AM	Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Jan-03-24 04:05PM	Agios Stock Whipsaws As It Looks To Rival Crispr, Vertex In A Key Market (Investor's Business Daily) +5.21%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
10:09AM	Agios Pharma Surged, And Then Pulled Back, After Testing A Thalassemia Drug (Investor's Business Daily)
09:26AM	Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug (Investor's Business Daily)
06:58AM	Midday movers: Apple, Tesla, Eli Lilly and more (Investing.com)
06:40AM	Agios' blood disorder drug meets goals of late-stage study (Reuters)
06:30AM	Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-02-24 07:00AM	Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (GlobeNewswire)
07:00PM	Loading…
Dec-09-23 07:00PM	Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-21-23 10:56AM	Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment (Zacks)
Nov-20-23 07:00AM	Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Nov-03-23 12:10PM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.10%
11:06AM	Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales (Zacks)
Nov-02-23 09:32AM	Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net Revenue (GuruFocus.com)
09:05AM	Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition (GlobeNewswire)
07:10AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 07:00AM	Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023 (GlobeNewswire)
Sep-07-23 11:30AM	Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report? (Zacks)
Aug-29-23 07:00AM	Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023 (GlobeNewswire)
Aug-10-23 06:08AM	The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake (American City Business Journals)
Aug-04-23 05:32PM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:10AM	Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line (Zacks)
06:04AM	Agios Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-03-23 11:53PM	Q2 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:55AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:54AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
06:35AM	Agios Reports Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire)
06:30AM	Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera (GlobeNewswire)
Jul-18-23 09:55AM	Should You Buy Agios Pharmaceuticals (AGIO) After Golden Cross? (Zacks)
Jul-17-23 09:55AM	Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet (Zacks)
Jul-13-23 07:00AM	Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023 (GlobeNewswire)
Jun-28-23 09:40AM	Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year? (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 02:23PM	Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat (Benzinga)
06:30AM	Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response (GlobeNewswire)
Jun-12-23 09:55AM	Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to Trade (Zacks)
Jun-05-23 07:00AM	Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023 (GlobeNewswire)
May-30-23 09:45AM	Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
May-25-23 09:55AM	Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect? (Zacks)
07:00AM	Agios Appoints Catherine Owen to Board of Directors (GlobeNewswire)
May-11-23 10:00AM	Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress (GlobeNewswire)
May-09-23 09:55AM	Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know (Zacks)
May-08-23 07:55AM	An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% Undervalued (Simply Wall St.)
May-05-23 10:50AM	Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
May-04-23 11:23PM	Q1 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +7.65%
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Agios Reports Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
Apr-19-23 07:00AM	Agios Appoints Jeffrey Capello to Board of Directors (GlobeNewswire)
Apr-13-23 07:00AM	Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire) +5.29%
Apr-12-23 08:00AM	Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero (PR Newswire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Apr-03-23 07:00AM	Agios Publishes 2023 Environmental, Social and Governance (ESG) Report (GlobeNewswire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 09:10AM	We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely (Simply Wall St.)
Mar-05-23 05:20AM	TipRanks Perfect 10 List: These 2 Healthcare Stocks Look Compelling at Current Levels (TipRanks)
Mar-02-23 08:26AM	Agios to Participate in March Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Agios Launches Red Cell Revolution in Recognition of Rare Disease Day (GlobeNewswire)
Feb-24-23 12:00PM	Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
11:49AM	Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss (Zacks)
Feb-23-23 08:45AM	Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates (Zacks)
08:38AM	Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:00AM	Agios Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-09-23 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-23 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023 (GlobeNewswire)
Jan-15-23 08:56AM	Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago (Simply Wall St.)
Jan-08-23 08:00PM	Agios Unveils 2023-2026 Value-driving Catalysts Enabling Companys Vision to Transform Patient Outcomes in Rare Diseases (GlobeNewswire)
Jan-03-23 05:57PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (GlobeNewswire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-21-22 08:00AM	Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 (GlobeNewswire)
Dec-11-22 07:00PM	Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-10-22 06:30PM	Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent - and -Thalassemia at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-06-22 07:00AM	Agios Appoints Tsveta Milanova as Chief Commercial Officer (GlobeNewswire)
Nov-30-22 08:00AM	Agios to Participate in December Investor Conference (GlobeNewswire)
Nov-17-22 05:52AM	The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup (American City Business Journals) +5.38%
Nov-11-22 11:03AM	Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients (Benzinga)
Nov-10-22 04:01PM	PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients (GlobeNewswire) +9.15%

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FOUSE JACQUALYN A	Director	Apr 10 '24	Sale	27.55	7,791	214,642	137,396	Apr 10 04:03 PM
FOUSE JACQUALYN A	Director	Apr 08 '24	Option Exercise	0.00	15,934	0	145,187	Apr 10 04:03 PM
Foster-Cheek Kaye I	Director	Mar 07 '24	Sale	31.62	1,285	40,632	5,524	Mar 11 04:09 PM
Foster-Cheek Kaye I	Director	Mar 06 '24	Sale	31.99	4,415	141,236	6,809	Mar 07 06:49 PM
Goff Brian	Chief Executive Officer	Mar 05 '24	Sale	32.57	4,156	135,361	53,780	Mar 05 04:10 PM
Burns James William	Chief Legal Officer	Mar 05 '24	Sale	32.57	2,642	86,050	34,518	Mar 05 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 05 '24	Sale	32.57	2,642	86,050	36,415	Mar 05 04:20 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	31.75	1,913	60,738	2,886	Mar 07 06:47 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	32.57	1,214	39,540	3,368	Mar 05 04:15 PM
Jones Cecilia	Chief Financial Officer	Mar 05 '24	Sale	32.57	672	21,887	14,840	Mar 05 04:18 PM
Foster-Cheek Kaye I	Director	Mar 05 '24	Sale	32.21	300	9,663	11,224	Mar 07 06:49 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '24	Option Exercise	0.00	3,127	0	5,718	Mar 05 04:15 PM
Goff Brian	Chief Executive Officer	Mar 01 '24	Option Exercise	0.00	8,500	0	57,936	Mar 05 04:10 PM
Burns James William	Chief Legal Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	38,518	Mar 05 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	40,415	Mar 05 04:20 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '24	Option Exercise	0.00	2,000	0	15,512	Mar 05 04:18 PM
Schenkein David P	Director	Feb 27 '24	Option Exercise	31.64	69,329	2,193,570	180,325	Feb 29 04:05 PM
Schenkein David P	Director	Feb 27 '24	Sale	34.67	69,329	2,403,592	122,854	Feb 29 04:05 PM
Schenkein David P	Director	Feb 26 '24	Option Exercise	31.64	20,411	645,804	143,265	Feb 27 04:04 PM
Schenkein David P	Director	Feb 26 '24	Sale	33.19	20,411	677,441	122,854	Feb 27 04:04 PM
Schenkein David P	Director	Feb 23 '24	Option Exercise	31.64	47,731	1,510,209	170,585	Feb 27 04:04 PM
Schenkein David P	Director	Feb 23 '24	Sale	33.05	47,731	1,577,510	122,854	Feb 27 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 20 '24	Sale	26.63	504	13,422	2,741	Feb 22 05:43 PM
Gheuens Sarah	Chief Medical Officer	Feb 14 '24	Sale	25.14	642	16,140	33,431	Feb 14 05:53 PM
Burns James William	Chief Legal Officer	Feb 14 '24	Sale	25.14	545	13,701	31,666	Feb 14 05:51 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14 '24	Sale	25.14	273	6,863	3,245	Feb 14 05:50 PM
Gheuens Sarah	Chief Medical Officer	Feb 12 '24	Option Exercise	0.00	2,162	0	34,073	Feb 14 05:53 PM
Burns James William	Chief Legal Officer	Feb 12 '24	Option Exercise	0.00	1,833	0	32,211	Feb 14 05:51 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 12 '24	Option Exercise	0.00	777	0	3,518	Feb 14 05:50 PM
FOUSE JACQUALYN A	Director	Jan 24 '24	Sale	21.64	10,722	232,024	129,253	Jan 24 04:22 PM
Goff Brian	Chief Executive Officer	Jan 24 '24	Sale	21.64	7,635	165,221	49,436	Jan 24 04:20 PM
Jones Cecilia	Chief Financial Officer	Jan 24 '24	Sale	21.64	1,886	40,813	13,069	Jan 24 04:23 PM
Gheuens Sarah	Chief Medical Officer	Jan 24 '24	Sale	21.64	1,708	36,961	31,911	Jan 24 04:24 PM
Burns James William	Chief Legal Officer	Jan 24 '24	Sale	21.64	1,708	36,961	30,378	Jan 24 04:25 PM
Milanova Tsveta	Chief Commercial Officer	Jan 24 '24	Sale	21.64	1,618	35,014	13,234	Jan 24 04:19 PM
Burns James William	Chief Legal Officer	Jan 20 '24	Option Exercise	0.00	5,750	0	32,086	Jan 24 04:25 PM
Gheuens Sarah	Chief Medical Officer	Jan 20 '24	Option Exercise	0.00	5,750	0	33,619	Jan 24 04:24 PM
Jones Cecilia	Chief Financial Officer	Jan 20 '24	Option Exercise	0.00	5,380	0	14,955	Jan 24 04:23 PM
FOUSE JACQUALYN A	Director	Jan 20 '24	Option Exercise	0.00	23,900	0	139,975	Jan 24 04:22 PM
Milanova Tsveta	Chief Commercial Officer	Jan 20 '24	Option Exercise	0.00	5,448	0	14,852	Jan 24 04:19 PM
Goff Brian	Chief Executive Officer	Jan 20 '24	Option Exercise	0.00	17,018	0	57,071	Jan 24 04:20 PM
Goff Brian	Chief Executive Officer	Jan 09 '24	Sale	22.99	12,066	277,397	40,053	Jan 09 04:28 PM
FOUSE JACQUALYN A	Director	Jan 09 '24	Sale	22.99	8,391	192,909	116,075	Jan 09 04:26 PM
Gheuens Sarah	Chief Medical Officer	Jan 09 '24	Sale	22.99	1,789	41,129	27,869	Jan 09 04:22 PM
Burns James William	Chief Legal Officer	Jan 09 '24	Sale	22.99	1,163	26,737	26,336	Jan 09 04:25 PM
FOUSE JACQUALYN A	Director	Jan 05 '24	Option Exercise	0.00	17,500	0	124,466	Jan 09 04:26 PM
Burns James William	Chief Legal Officer	Jan 05 '24	Option Exercise	0.00	3,250	0	27,499	Jan 09 04:25 PM
Gheuens Sarah	Chief Medical Officer	Jan 05 '24	Option Exercise	0.00	5,000	0	29,658	Jan 09 04:22 PM
Goff Brian	Chief Executive Officer	Jan 05 '24	Option Exercise	0.00	25,527	0	52,119	Jan 09 04:28 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '24	Sale	22.32	2,902	64,773	9,404	Jan 05 04:10 PM
Milanova Tsveta	Chief Commercial Officer	Jan 03 '24	Option Exercise	0.00	8,475	0	12,306	Jan 05 04:10 PM
Jones Cecilia	Chief Financial Officer	Sep 28 '23	Sale	24.79	2,179	54,017	9,575	Sep 28 04:02 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '23	Option Exercise	0.00	7,472	0	11,754	Sep 28 04:02 PM
Burns James William	Chief Legal Officer	Aug 17 '23	Sale	26.28	6,395	168,061	23,890	Aug 21 04:03 PM
Ballal Rahul D.	Director	Aug 11 '23	Option Exercise	0.00	2,302	0	2,302	Aug 15 04:06 PM
Smith Cynthia	Director	Aug 11 '23	Option Exercise	0.00	2,302	0	2,302	Aug 15 04:04 PM
Foster-Cheek Kaye I	Director	Aug 09 '23	Option Exercise	18.09	25,000	452,250	36,524	Aug 11 04:04 PM
Foster-Cheek Kaye I	Director	Aug 09 '23	Sale	25.96	25,000	648,888	11,524	Aug 11 04:04 PM
Goff Brian	Chief Executive Officer	Aug 08 '23	Option Exercise	0.00	22,691	0	36,770	Aug 10 04:07 PM
Goff Brian	Chief Executive Officer	Aug 08 '23	Sale	25.48	10,178	259,335	26,592	Aug 10 04:07 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 07 '23	Sale	25.39	2,918	74,096	2,741	Aug 09 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 01 '23	Option Exercise	0.00	4,150	0	6,891	Aug 02 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 01 '23	Sale	26.26	1,232	32,352	5,659	Aug 02 04:02 PM
Goff Brian	Chief Executive Officer	Jun 30 '23	Sale	28.36	11,449	324,694	14,079	Jun 30 04:05 PM
FOUSE JACQUALYN A	Director	Jun 30 '23	Sale	28.36	10,718	303,962	106,966	Jun 30 04:07 PM
Burns James William	Chief Legal Officer	Jun 30 '23	Sale	28.36	1,707	48,411	30,285	Jun 30 04:09 PM
Gheuens Sarah	Chief Medical Officer	Jun 30 '23	Sale	28.36	1,707	48,411	24,159	Jun 30 04:06 PM
Milanova Tsveta	Chief Commercial Officer	Jun 30 '23	Sale	28.36	1,618	45,886	3,831	Jun 30 04:02 PM
Jones Cecilia	Chief Financial Officer	Jun 30 '23	Sale	28.36	1,597	45,291	3,783	Jun 30 04:03 PM
Milanova Tsveta	Chief Commercial Officer	Jun 28 '23	Option Exercise	0.00	5,449	0	5,449	Jun 30 04:02 PM
Jones Cecilia	Chief Financial Officer	Jun 28 '23	Option Exercise	0.00	5,380	0	5,380	Jun 30 04:03 PM
FOUSE JACQUALYN A	Director	Jun 28 '23	Option Exercise	0.00	23,900	0	117,684	Jun 30 04:07 PM
Goff Brian	Chief Executive Officer	Jun 28 '23	Option Exercise	0.00	25,528	0	25,528	Jun 30 04:05 PM
Gheuens Sarah	Chief Medical Officer	Jun 28 '23	Option Exercise	0.00	5,750	0	25,866	Jun 30 04:06 PM
Burns James William	Chief Legal Officer	Jun 28 '23	Option Exercise	0.00	5,750	0	31,992	Jun 30 04:09 PM
Schenkein David P	Director	Jun 21 '23	Option Exercise	0.00	4,975	0	122,854	Jun 23 04:34 PM
Foster-Cheek Kaye I	Director	Jun 21 '23	Option Exercise	0.00	4,975	0	11,524	Jun 23 04:38 PM
Ho Maykin	Director	Jun 21 '23	Option Exercise	0.00	4,975	0	11,524	Jun 23 04:37 PM
Scadden David	Director	Jun 21 '23	Option Exercise	0.00	4,975	0	12,095	Jun 23 04:36 PM

Open in Screener

MNKD

Mannkind Corp

Apr 23 • 04:00PM ET

4.16

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB PBE IWO SCHA VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.05	Insider Own	3.76%	Shs Outstand	270.03M	Perf Week	2.72%
Market Cap	1.12B	Forward P/E	16.92	EPS next Y	0.25	Insider Trans	-2.03%	Shs Float	260.24M	Perf Month	-15.45%
Income	-11.94M	PEG	-	EPS next Q	0.03	Inst Own	49.50%	Short Float	11.82%	Perf Quarter	20.58%
Sales	198.96M	P/S	5.65	EPS this Y	427.50%	Inst Trans	8.26%	Short Ratio	10.75	Perf Half Y	-1.19%
Book/sh	-0.91	P/B	-	EPS next Y	87.63%	ROA	-3.10%	Short Interest	30.76M	Perf Year	2.21%
Cash/sh	1.09	P/C	3.81	EPS next 5Y	35.60%	ROE	-	52W Range	3.17 - 5.75	Perf YTD	14.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.58%	ROI	-11.45%	52W High	-27.65%	Beta	1.34
Dividend TTM	-	Quick Ratio	3.31	Sales past 5Y	55.42%	Gross Margin	68.45%	52W Low	31.23%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	3.59	EPS Y/Y TTM	86.73%	Oper. Margin	5.32%	RSI (14)	45.02	Volatility	4.31% 4.81%
Employees	414	Debt/Eq	-	Sales Y/Y TTM	99.42%	Profit Margin	-6.00%	Recom	1.40	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	106.31%	Payout	-	Rel Volume	0.00	Prev Close	4.16
Sales Surprise	8.40%	EPS Surprise	-100.00%	Sales Q/Q	62.16%	Earnings	Feb 27 AMC	Avg Volume	2.86M	Price	4.16
SMA20	-3.68%	SMA50	-3.06%	SMA200	1.49%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-23	Initiated	Wedbush	Outperform	$10
May-14-21	Initiated	RBC Capital Mkts	Sector Perform	$5
Dec-24-19	Initiated	Oppenheimer	Outperform	$2.50
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight	$3
May-14-19	Initiated	BTIG Research	Buy	$3
Mar-04-19	Initiated	SVB Leerink	Outperform	$3
Feb-22-19	Initiated	SVB Leerink	Outperform	$3
Feb-28-18	Downgrade	Maxim Group	Hold → Sell	$1
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy	$7
Oct-06-17	Reiterated	Maxim Group	Buy	$4 → $7
Aug-11-17	Initiated	Maxim Group	Buy	$4
May-10-16	Reiterated	RBC Capital Mkts	Underperform	$0.15 → $0.20
May-10-16	Reiterated	Piper Jaffray	Underweight	$0.05 → $0.10
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform	$1 → $0.15
Jan-06-16	Reiterated	Piper Jaffray	Underweight	$1.50 → $0.05
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform	$9 → $1
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform	$10 → $9
May-11-15	Reiterated	MLV & Co	Hold	$7 → $4

Show Previous Ratings

Apr-03-24 06:00AM	MannKind Repays Certain Debt Obligations (GlobeNewswire)
Mar-26-24 04:05PM	MannKind Announces CFO Transition (GlobeNewswire)
Mar-25-24 11:45AM	Jim Cramer Says You Should Avoid These 11 Stocks (Insider Monkey)
Mar-11-24 06:05AM	INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps (GlobeNewswire) -12.52%
Mar-05-24 06:05AM	MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 (GlobeNewswire)
01:01PM	Loading…
Mar-04-24 01:01PM	MannKind Corporation Announces Participation at Upcoming Conferences (GlobeNewswire)
Feb-28-24 09:30AM	MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:11AM	Q4 2023 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
01:00AM	MannKind (MNKD) Q4 2023 Earnings Call Transcript (Motley Fool)
Feb-27-24 06:00PM	Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings (Zacks) +5.59%
05:35PM	MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:46PM	MannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023 (GuruFocus.com)
04:00PM	MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update (GlobeNewswire)
Feb-20-24 06:00AM	MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 (GlobeNewswire)
Feb-15-24 06:05AM	MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza (GlobeNewswire)
12:30PM	Loading…
Feb-12-24 12:30PM	13 Best NASDAQ Penny Stocks To Invest In (Insider Monkey)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-02-24 06:05AM	MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million (GlobeNewswire) +7.69%
Dec-28-23 06:00AM	MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-23 09:01PM	Insider Sell: CEO Michael Castagna Offloads 200,482 Shares of MannKind Corp (MNKD) (GuruFocus.com)
Nov-08-23 03:27PM	MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 09:15PM	MannKind (MNKD) Q3 2023 Earnings Call Transcript (Motley Fool)
05:30PM	MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:12PM	MannKind: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	MannKind Corporation Reports 2023 Third Quarter Financial Results (GlobeNewswire)
Nov-06-23 06:15AM	MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes (GlobeNewswire) -7.07%
Nov-01-23 10:01AM	Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks) -6.06%
Oct-31-23 04:00PM	MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023 (GlobeNewswire)
Oct-30-23 06:15AM	MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent (GlobeNewswire) +6.39%
Sep-07-23 07:08AM	7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth (InvestorPlace)
06:00AM	Loading…
Sep-05-23 06:00AM	MannKind Corporation Announces Participation at Upcoming Conferences (GlobeNewswire)
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 12:44PM	3 Biotech Stocks to Sell in August Before They Crash and Burn (InvestorPlace)
Aug-08-23 05:16PM	Why MannKind Stock Soared 19% Higher on Tuesday (Motley Fool) +18.48%
11:33AM	Q2 2023 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
12:00AM	MannKind (MNKD) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-07-23 06:00PM	Here's What Key Metrics Tell Us About MannKind (MNKD) Q2 Earnings (Zacks)
05:25PM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
04:16PM	MannKind: Q2 Earnings Snapshot (AP Finance)
04:00PM	MannKind Corporation Reports 2023 Second Quarter Financial Results (GlobeNewswire)
Aug-01-23 06:00AM	MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-31-23 04:00PM	MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023 (GlobeNewswire)
Jul-13-23 07:31AM	Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now (InvestorPlace)
07:00AM	7 Biotech Stocks to Sell in July (InvestorPlace)
Jun-22-23 06:05AM	MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D) (GlobeNewswire)
Jun-11-23 08:05AM	Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone (GlobeNewswire)
May-28-23 07:49PM	7 Overvalued Penny Stocks to Sell Before June 2023 (InvestorPlace)
May-24-23 08:30AM	Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer (GlobeNewswire)
May-23-23 09:50AM	3 Biotech Stocks to Avoid Like the Plague (InvestorPlace)
May-10-23 12:02PM	Why Shares of MannKind Are Up Wednesday (Motley Fool) +15.79%
06:00AM	MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-09-23 11:30PM	MannKind (MNKD) Q1 2023 Earnings Call Transcript (Motley Fool)
08:21PM	CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results (GlobeNewswire)
05:15PM	MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:18PM	MannKind: Q1 Earnings Snapshot (AP Finance)
04:00PM	Mannkind Corporation Reports 2023 First Quarter Financial Results (GlobeNewswire)
01:41PM	MannKind Corporation (NASDAQ:MNKD) is favoured by institutional owners who hold 54% of the company (Simply Wall St.)
May-02-23 05:00PM	MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023 (GlobeNewswire) -6.06%
Mar-27-23 04:05PM	Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer (GlobeNewswire)
Mar-14-23 02:26PM	Breakeven On The Horizon For MannKind Corporation (NASDAQ:MNKD) (Simply Wall St.)
Mar-07-23 05:00PM	MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-24-23 01:30AM	MannKind (MNKD) Q4 2022 Earnings Call Transcript (Motley Fool)
Feb-23-23 04:00PM	MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results (GlobeNewswire)
Feb-22-23 06:05AM	MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference (GlobeNewswire)
Feb-16-23 05:00PM	MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023 (GlobeNewswire)
Feb-15-23 12:46PM	As MannKind Corporation (NASDAQ:MNKD) gains 6.3%, insiders who bought last year may be wishing they had bet higher (Simply Wall St.)
Feb-10-23 05:00PM	Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-09-23 08:50AM	Here's What Could Help MannKind (MNKD) Maintain Its Recent Price Strength (Zacks)
Jan-24-23 06:00AM	MannKind Corporation to Participate in the Lytham Partners Investor Select Conference (GlobeNewswire) +6.79%
Jan-23-23 06:05AM	MannKinds Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease (GlobeNewswire)
Jan-18-23 08:00AM	3 Biotech Stocks Under $15 Worth a Second Look in 2023 (Motley Fool)
Jan-17-23 06:36AM	MannKind's (NASDAQ:MNKD) investors will be pleased with their impressive 183% return over the last three years (Simply Wall St.) -5.38%
Jan-05-23 06:00AM	MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 07:11AM	Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 44% Undervaluation? (Simply Wall St.)
Dec-06-22 09:55AM	After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright (Zacks)
Nov-30-22 12:29PM	MannKind Corporation (NASDAQ:MNKD) is a favorite amongst institutional investors who own 52% (Simply Wall St.) +5.64%
Nov-10-22 06:05AM	MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting (GlobeNewswire) +10.10%
05:31AM	MannKind Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 04:30PM	MannKind Corporation (MNKD) Q3 2022 Earnings Call Transcript (Motley Fool)
09:15AM	MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	MannKind Corporation Reports 2022 Third Quarter Financial Results (GlobeNewswire)
Nov-01-22 06:00AM	MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022 (GlobeNewswire)
Sep-29-22 11:38AM	7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up (InvestorPlace) -5.97%
06:13AM	When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)? (Simply Wall St.)
Sep-21-22 05:00PM	MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-19-22 06:00AM	7 Penny Stocks That Actually Have a Buy Rating (InvestorPlace)
Sep-08-22 01:18PM	A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders (Simply Wall St.) +5.32%
Sep-06-22 06:15AM	Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine (GlobeNewswire) -5.29%
Sep-01-22 06:00AM	MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.04%
Aug-25-22 09:09AM	10 Stocks That Jumped After Jim Cramers Negative Call (Insider Monkey)
Aug-19-22 06:18AM	Analysts Are Betting On MannKind Corporation (NASDAQ:MNKD) With A Big Upgrade This Week (Simply Wall St.)
Aug-16-22 09:03AM	Jim Cramer Recommends Selling These 10 Stocks in August (Insider Monkey)
Aug-10-22 07:19AM	MannKind's (NASDAQ:MNKD) investors will be pleased with their stellar 268% return over the last three years (Simply Wall St.)
05:30AM	MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-09-22 05:15PM	MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.98%
05:00PM	Edited Transcript of MNKD.OQ earnings conference call or presentation 9-Aug-22 9:00pm GMT (Thomson Reuters StreetEvents)
04:00PM	MannKind Corporation Reports 2022 Second Quarter Financial Results (GlobeNewswire)
Aug-02-22 06:00AM	MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022 (GlobeNewswire) +10.06%
Aug-01-22 07:35PM	Why Shares of MannKind Corporation Climbed 10.4% on Monday (Motley Fool)
06:00AM	MannKind Corporation to Participate in the BTIG Biotechnology Conference (GlobeNewswire)

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Castagna Michael	Chief Executive Officer	Dec 15 '23	Sale	4.00	90,482	361,928	2,148,665	Dec 15 09:00 PM
Castagna Michael	Chief Executive Officer	Dec 14 '23	Sale	4.00	110,000	440,000	2,239,147	Dec 15 09:00 PM
Castagna Michael	Chief Executive Officer	Nov 01 '23	Sale	4.25	10,000	42,500	2,349,147	Nov 02 09:00 PM
Castagna Michael	Chief Executive Officer	Oct 02 '23	Sale	4.61	10,000	46,100	2,359,147	Oct 02 09:00 PM
Castagna Michael	Chief Executive Officer	Sep 01 '23	Sale	4.61	10,000	46,100	2,436,039	Sep 05 09:00 PM
Thomson David	EVP Genl Counsel & Secretary	Aug 28 '23	Sale	4.78	8,100	38,738	798,835	Aug 28 09:00 PM
Castagna Michael	Chief Executive Officer	Aug 01 '23	Sale	4.57	10,000	45,686	2,496,735	Aug 01 09:00 PM
Castagna Michael	Chief Executive Officer	Jul 03 '23	Sale	4.07	10,000	40,701	2,506,735	Jul 05 06:00 AM
Castagna Michael	Chief Executive Officer	Jun 01 '23	Sale	4.53	10,000	45,302	2,516,735	Jun 02 09:00 PM
Castagna Michael	Chief Executive Officer	May 26 '23	Sale	4.50	75,000	337,335	2,526,735	May 26 09:00 PM
Castagna Michael	Chief Executive Officer	May 25 '23	Sale	4.59	75,000	344,468	2,601,735	May 26 09:00 PM
Castagna Michael	Chief Executive Officer	May 24 '23	Sale	4.69	150,000	702,780	2,331,735	May 24 09:00 PM
Thomson David	EVP Genl Counsel & Secretary	May 24 '23	Sale	4.68	95,576	447,754	735,263	May 24 09:00 PM
Binder Steven B.	Chief Financial Officer	May 24 '23	Sale	4.67	47,810	223,512	838,324	May 24 09:00 PM
Castagna Michael	Chief Executive Officer	May 05 '23	Sale	4.00	10,000	40,000	2,020,128	May 05 09:00 PM

Open in Screener

PAGP

Plains GP Holdings LP

Apr 23 • 04:00PM ET

18.86

Dollar change 0.00
Percentage change 0.00	%

Energy • Oil & Gas Midstream • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PAGP Plains GP Holdings LP daily Stock Chart

Held by: EMLP MLPX SURI AVUV UMI VDE SYLD EIPX SMIG ENFR

Index	-	P/E	18.58	EPS (ttm)	1.02	Insider Own	2.70%	Shs Outstand	196.42M	Perf Week	3.40%
Market Cap	3.72B	Forward P/E	12.04	EPS next Y	1.57	Insider Trans	0.00%	Shs Float	191.80M	Perf Month	5.84%
Income	198.00M	PEG	-	EPS next Q	0.39	Inst Own	83.92%	Short Float	5.69%	Perf Quarter	14.72%
Sales	48.70B	P/S	0.08	EPS this Y	46.80%	Inst Trans	1.43%	Short Ratio	4.95	Perf Half Y	16.92%
Book/sh	7.88	P/B	2.39	EPS next Y	5.63%	ROA	0.69%	Short Interest	10.92M	Perf Year	36.96%
Cash/sh	2.30	P/C	8.21	EPS next 5Y	0.00%	ROE	12.89%	52W Range	12.59 - 19.77	Perf YTD	18.24%
Dividend Est.	1.27 (6.73%)	P/FCF	1.72	EPS past 5Y	-3.03%	ROI	2.17%	52W High	-4.60%	Beta	1.50
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	13.84%	Gross Margin	3.57%	52W Low	49.86%	ATR (14)	0.33
Dividend Ex-Date	Jul 28, 2022	Current Ratio	0.98	EPS Y/Y TTM	44.56%	Oper. Margin	2.84%	RSI (14)	59.61	Volatility	1.89% 1.81%
Employees	4200	Debt/Eq	5.23	Sales Y/Y TTM	-14.81%	Profit Margin	0.41%	Recom	2.33	Target Price	19.46
Option/Short	Yes / Yes	LT Debt/Eq	4.90	EPS Q/Q	321.11%	Payout	105.38%	Rel Volume	0.00	Prev Close	18.86
Sales Surprise	10.53%	EPS Surprise	-32.09%	Sales Q/Q	-2.28%	Earnings	Feb 09 AMC	Avg Volume	2.21M	Price	18.86
SMA20	0.95%	SMA50	5.81%	SMA200	15.18%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Resumed	Scotiabank	Sector Outperform	$23
Oct-06-23	Resumed	Goldman	Sell	$13.50
Sep-25-23	Downgrade	Barclays	Equal Weight → Underweight	$15
Sep-06-23	Downgrade	Citigroup	Buy → Neutral	$14 → $15.50
Apr-21-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $17
Dec-09-22	Initiated	Citigroup	Buy	$14
Nov-21-22	Downgrade	JP Morgan	Overweight → Neutral	$15 → $14
Aug-15-22	Upgrade	Stifel	Hold → Buy	$16
Aug-01-22	Upgrade	Seaport Research Partners	Neutral → Buy	$13
Jul-19-22	Upgrade	BofA Securities	Underperform → Neutral	$12
May-12-22	Upgrade	Credit Suisse	Neutral → Outperform	$13 → $14
May-02-22	Resumed	Truist	Buy	$13
Jan-25-22	Upgrade	Bernstein	Mkt Perform → Outperform	$14.50
Jan-10-22	Upgrade	Wolfe Research	Peer Perform → Outperform
Nov-29-21	Resumed	Barclays	Equal Weight
Oct-29-21	Downgrade	Seaport Research Partners	Buy → Neutral
Sep-28-21	Resumed	BofA Securities	Underperform	$10.50
Jul-16-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$13
Mar-11-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-01-21	Resumed	Scotiabank	Sector Outperform

Show Previous Ratings

Apr-04-24 04:45PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of First-Quarter 2024 Earnings (GlobeNewswire)
Feb-27-24 03:26PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Feb-12-24 08:18AM	Plains GP Holdings, L.P. (NASDAQ:PAGP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-09-24 02:15PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
08:37AM	Plains GP Holdings LP (PAGP) Reports Solid Earnings Growth and Positive Outlook for 2024 (GuruFocus.com)
08:00AM	Loading…
08:00AM	Plains GP: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Plains All American Reports Fourth-Quarter and Full-Year 2023 Results; Announces 2024 Guidance (GlobeNewswire)
Jan-08-24 05:30PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Fourth-Quarter 2023 Earnings (GlobeNewswire)
Nov-06-23 09:03AM	Plains GP Holdings, L.P. (NASDAQ:PAGP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 03:22PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
10:40AM	Plains GP Holdings LP (PAGP) Reports Q3 2023 Earnings, Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Plains GP: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Plains All American Reports Third-Quarter 2023 Results & Raises 2023 Guidance (GlobeNewswire)
Oct-11-23 09:39PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Oct-06-23 08:02AM	5 Low Price-to-Sales Stocks Poised to Deliver Robust Value (Zacks)
05:30PM	Loading…
Oct-05-23 05:30PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of Third-Quarter 2023 Earnings (GlobeNewswire)
05:30PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions (GlobeNewswire)
06:33AM	Zacks.com featured highlights Pilgrim's Pride, Urban Outfitters, Plains GP, DMC Global and Vistra (Zacks)
Oct-04-23 06:32PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
01:56PM	Hedge Fund and Insider Trading News: Israel Englander, Wellington Management, Balyasny Asset Management, CABA Capital, Nike Inc (NKE), Plains GP Holdings, L.P. (PAGP), and More (Insider Monkey)
08:23AM	Bet on These 3 Juicy Dividend Yielding Energy Stocks (Zacks)
Sep-26-23 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
08:50AM	Despite Fast-paced Momentum, Plains GP (PAGP) Is Still a Bargain Stock (Zacks)
Sep-25-23 09:43AM	Plains GP Holdings: Consistent Inflows Boosts Shares (FX Empire)
Sep-22-23 08:31AM	Zacks.com featured highlights include Boise Cascade, M/I Homes, The ODP, EnerSys and Plains GP Holdings (Zacks)
Sep-21-23 07:17AM	Tap These 5 Bargain Stocks With Attractive EV-to-EBITDA Ratios (Zacks)
Sep-20-23 08:00AM	Get a Buoyant Portfolio With These 5 Low Price-to-Sales Stocks (Zacks)
Sep-07-23 09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
Sep-06-23 04:09PM	4 Energy Stocks to Buy for Growth & Lofty Dividends (Zacks)
09:36AM	Constellation Brands upgraded, Block downgraded: Wall Street's top analyst calls (The Fly)
07:58AM	Loading…
Sep-01-23 07:58AM	7 A-Rated Oil and Gas Stocks for Your September Buy List (InvestorPlace)
Aug-31-23 12:20PM	Why Plains GP (PAGP) Might be Well Poised for a Surge (Zacks)
12:00PM	Plains GP Holdings (PAGP) Is Up 0.63% in One Week: What You Should Know (Zacks)
Aug-23-23 05:00AM	Zacks.com featured highlights Boise Cascade, JinkoSolar, CEMEX, EnerSys and Plains GP (Zacks)
Aug-22-23 06:40AM	Pick These 5 Bargain Stocks With Attractive EV-to-EBITDA Ratios (Zacks)
Aug-17-23 08:50AM	Why Fast-paced Mover Plains GP (PAGP) Is a Great Choice for Value Investors (Zacks)
Aug-15-23 03:00PM	Are You Looking for a Top Momentum Pick? Why Plains GP Holdings (PAGP) is a Great Choice (Zacks)
Aug-14-23 08:02AM	3 Oil Stocks That Could Gush as Demand Outlook Grows (InvestorPlace)
Aug-11-23 06:35PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
08:33AM	4 Oil Pipeline Stocks to Gain Despite Industry Challenges (Zacks)
Aug-10-23 06:58AM	10 Energy Stocks with Insider Buying (Insider Monkey)
Aug-07-23 06:31PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
05:00AM	Zacks.com featured highlights Covenant Logistics, Group 1 Automotive, UFP, Plains GP and Motorcar Parts of America (Zacks)
Aug-05-23 12:18AM	Q2 2023 Plains GP Holdings LP Earnings Call (Thomson Reuters StreetEvents)
Aug-04-23 04:39PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
08:09AM	Plains GP: Q2 Earnings Snapshot (AP Finance)
08:00AM	Plains All American Reports Second-Quarter 2023 Results and Provides Updated 2023 Guidance (GlobeNewswire)
06:49AM	5 Value Stocks With Impressive EV-to-EBITDA Ratios to Scoop Up (Zacks)
Jul-24-23 04:30PM	Plains Publishes 2022 Sustainability Report (GlobeNewswire)
Jul-13-23 09:32AM	3 Energy Stocks That AI is Loving in July (InvestorPlace)
Jul-06-23 04:16PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of Second-Quarter 2023 Earnings (GlobeNewswire)
04:15PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions (GlobeNewswire)
Jun-08-23 09:35AM	Is Plains Group (PAGP) a Worthy Pick for Value Investors? (Zacks)
May-22-23 05:23PM	Inside Scoop: 10 Mid-Cap Stocks with Recent Insider Purchases (Insider Monkey)
May-11-23 08:11PM	Insiders Load Up on These 2 Dividend Stocks With Impressive Yields of 8% or More (TipRanks)
May-09-23 06:40AM	Daily Vickers Top Buyers & Sellers for 05/09/2023 (Argus Research)
May-05-23 02:59PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research) +5.39%
08:14AM	Plains GP: Q1 Earnings Snapshot (AP Finance)
08:00AM	Plains All American Reports First-Quarter 2023 Results; Reaffirms 2023 Guidance (GlobeNewswire)
Apr-20-23 08:50AM	Despite Fast-paced Momentum, Plains GP (PAGP) Is Still a Bargain Stock (Zacks)
Apr-06-23 05:16PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of First-Quarter 2023 Earnings (GlobeNewswire)
05:15PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions (GlobeNewswire)
Mar-01-23 04:22PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Feb-13-23 04:15PM	Plains All American Completes Divestiture of Interest in Keyera Fort Saskatchewan Facility (GlobeNewswire)
10:55AM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Feb-09-23 11:06AM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Feb-08-23 04:16PM	Plains All American Reports Fourth-Quarter and Full-Year 2022 Results; Announces 2023 Guidance (GlobeNewswire)
Jan-09-23 04:16PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of Fourth-Quarter and Full-Year 2022 Earnings (GlobeNewswire)
04:15PM	Plains All American Pipeline and Plains GP Holdings Announce Distributions (GlobeNewswire)
Jan-04-23 04:15PM	Plains All American Announces Officer Appointments (GlobeNewswire)
Dec-14-22 04:15PM	Plains All American Announces Sale of Minority Ownership Interest in Keyera Fort Saskatchewan Joint Venture (GlobeNewswire)
Nov-02-22 04:16PM	Plains All American Reports Third-Quarter 2022 Results, Increases 2022 Guidance and Announces Multi-Year Capital Allocation Framework (GlobeNewswire)
04:05PM	Western Midstream Partners, Enbridge and Plains Announce Cactus II Pipeline Transaction (GlobeNewswire)
Oct-25-22 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
Oct-10-22 04:41PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of Third-Quarter 2022 Earnings & Quarterly Earnings Timing for 2023 (GlobeNewswire)
04:40PM	Plains All American Pipeline and Plains GP Holdings Announce Distributions (GlobeNewswire)
Aug-16-22 04:16PM	Plains Midstream Canada Pursuing Fort Saskatchewan Facility Expansion (GlobeNewswire)
Aug-03-22 04:16PM	Plains All American Reports Second-Quarter 2022 Results (GlobeNewswire)
Jul-28-22 09:05AM	Plains All American Releases 2021 Sustainability Report (GlobeNewswire)
Jul-27-22 04:45PM	Plains All American Pipeline, L.P. and Plains GP Holdings Announce Appointment of New Board Member (GlobeNewswire)
Jul-20-22 12:45PM	3 Reasons Growth Investors Will Love Plains GP (PAGP) (Zacks)
09:55AM	Does Plains GP (PAGP) Have the Potential to Rally 34% as Wall Street Analysts Expect? (Zacks)
Jul-08-22 07:16AM	Zacks.com featured highlights include United Natural Foods, PBF Energy, Plains GP Holdings, ArcBest Corporation and SM Energy (Zacks)
Jul-07-22 05:31PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of Second-Quarter 2022 Earnings (GlobeNewswire) +5.41%
05:30PM	Plains All American Pipeline and Plains GP Holdings Announce Distributions (GlobeNewswire)
07:15AM	5 Stocks With Impressive EV-to-EBITDA Ratios to Scoop Up (Zacks)
May-04-22 04:16PM	Plains All American Reports First-Quarter 2022 Results (GlobeNewswire)
Apr-21-22 02:00PM	Atura Power and Plains All American Sign MOU for Underground Hydrogen Storage Feasibility (GlobeNewswire)
Apr-05-22 05:01PM	Plains All American Pipeline and Plains GP Holdings Announce Timing of First-Quarter 2022 Earnings (GlobeNewswire)
05:00PM	Plains All American Pipeline and Plains GP Holdings Announce Distributions (GlobeNewswire)
Apr-04-22 04:16PM	Plains All American Announces Officer Promotion and Appointment (GlobeNewswire)
Apr-01-22 09:40AM	Are Investors Undervaluing These Oils-Energy Stocks Right Now? (Zacks)
Mar-18-22 09:35AM	Williams (WMB) to Acquire Trace Midstream's Assets for $950M (Zacks)
Mar-17-22 07:45AM	Zacks.com featured highlights include MarineMax, AdvanSix, USA Truck, Greif, and Plains GP Holdings (Zacks)
Mar-16-22 09:40AM	Should Value Investors Buy These Oils-Energy Stocks? (Zacks)
06:23AM	Tap These 5 Bargain Stocks With Amazingly Low EV-to-EBITDA Ratios (Zacks)
Mar-11-22 10:00AM	How Much Upside is Left in Plains GP (PAGP)? Wall Street Analysts Think 38% (Zacks)
Mar-02-22 12:45PM	Here is Why Growth Investors Should Buy Plains GP (PAGP) Now (Zacks)
Feb-15-22 04:44AM	Zacks.com featured highlights include: KB Home, Plains GP Holdings, L.P., GMS Inc. , MarineMax, Inc. and Hillenbrand, Inc (Zacks)
Feb-14-22 10:00AM	How Much Upside is Left in Plains GP (PAGP)? Wall Street Analysts Think 41% (Zacks)

Plains GP Holdings LP owns and operates midstream energy infrastructure and provides logistics services primarily for crude oil, natural gas liquids and natural gas through its indirect investment in Plains All American Pipeline, L.P. The firm operates through the following segments: Transportation, Facilities and Supply and Logistics. The Transportation segment consists of fee-based activities associated with transporting crude oil and NGL on pipelines, gathering systems, trucks and barges. The Facilities segment consists of fee-based activities associated with providing storage, terminalling and throughput services primarily for crude oil, NGL and natural gas, as well as NGL fractionation and isomerization services and natural gas and condensate processing services. The Supply and Logistics segment consists of storage of inventory during contango market conditions and the seasonal storage of NGL, purchase of NGL from producers, refiners, processors and other marketers, extraction of NGL from gas processed at the facilities. The company was founded in July 2013 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chiang Willie CW	Chairman & CEO	Sep 28 '23	Buy	16.24	62,000	1,006,694	318,704	Sep 29 11:48 AM
McCarthy Kevin S	Director	Aug 14 '23	Option Exercise	0.00	11,400	0	110,469	Aug 16 07:25 PM
DeSanctis Ellen	Director	Aug 14 '23	Option Exercise	0.00	11,400	0	21,400	Aug 16 07:23 PM
Burk Victor	Director	Aug 14 '23	Option Exercise	0.00	16,620	0	28,633	Aug 16 07:21 PM
RAYMOND JOHN T	Director	Aug 14 '23	Option Exercise	0.00	15,570	0	272,504	Aug 16 07:31 PM
Pruner Alexandra	Director	Aug 14 '23	Option Exercise	0.00	16,620	0	38,004	Aug 16 07:28 PM
PETERSEN GARY R	Director	Aug 14 '23	Option Exercise	0.00	16,620	0	25,254	Aug 16 07:27 PM
Ziemba Lawrence Michael	Director	Aug 14 '23	Option Exercise	0.00	17,880	0	44,890	Aug 16 07:39 PM
Temple Chris	Director	Aug 14 '23	Option Exercise	0.00	16,620	0	40,249	Aug 16 07:37 PM
SHACKOULS BOBBY S	Director	Aug 14 '23	Option Exercise	0.00	16,620	0	26,005	Aug 16 07:34 PM
Chiang Willie CW	Chairman & CEO	May 08 '23	Buy	13.25	75,000	993,525	256,704	May 08 06:37 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AGIO

Agios Pharmaceuticals Inc

MNKD

Mannkind Corp

PAGP

Plains GP Holdings LP

Upgrade your FINVIZ experience